WASHINGTON, D.C.— Acorda Therapeutics, Inc. announced May 20 it will discontinue development of PLUMIAZ™ (diazepam) Nasal Spray, an investigational therapy which was being studied for the treatment of seizure clusters in people with epilepsy. Data from ongoing clinical trials do not demonstrate its bioequivalence to Diastat® gel, which is needed for New Drug Applications (NDA).
March 25, 2020
Study Finds Pregabalin (Lyrica®) Adjunctive Therapy Significantly Reduces Seizure Rate in Children One Month to Over Four Years with Focal Onset Seizures
Pregabalin 14 mg/kg/d (but not 7 mg/kg/d) significantly reduced seizure rate in children with focal-onset seizures, when assessed using V?EEG, compared with placebo.
March 24, 2020
Study Finds Levetiracetam Not Significantly Better Than Phenytoin in Ending Seizures in Patients with Established Status Epilepticus
Moderate-quality evidence suggested that levetiracetam was not significantly superior to phenytoin in seizure cessation in patients with established status epilepticus.